Actions for Avian Diagnostic and Therapeutic Antibodies [electronic resource].

Email RIS file
Bookmark
Report an Issue

Avian Diagnostic and Therapeutic Antibodies [electronic resource].

Published
Washington, D.C. : United States. Dept. of Energy. Office of Science, 2012.
Oak Ridge, Tenn. : Distributed by the Office of Scientific and Technical Information, U.S. Dept. of Energy.
Physical Description
123 kb : digital, PDF file
Additional Creators
University of North Dakota, United States. Department of Energy. Office of Science, and United States. Department of Energy. Office of Scientific and Technical Information
Access Online

Availability

I Want It
I Want It

Finding items...

Restrictions on Access
Free-to-read Unrestricted online access
Summary
A number of infectious agents have the potential of causing significant clinical symptomology and even death, but dispite this, the number of incidence remain below the level that supports producing a vaccine. Therapeutic antibodies provide a viable treatment option for many of these diseases. We proposed that antibodies derived from West Nile Virus (WNV) immunized geese would be able to treat WNV infection in mammals and potential humans. We demonstrated that WNV specific goose antibodies are indeed successful in treating WNV infection both prophylactically and therapeutically in a golden hamster model. We demonstrated that the goose derived antibodies are non-reactogenic, i.e. do not cause an inflammatory response with multiple exposures in mammals. We also developed both a specific pathogen free facility to house the geese during the antibody production phase and a patent-pending purification process to purify the antibodies to greater than 99% purity. Therefore, the success of these study will allow a cost effective rapidly producible therapeutic toward clinical testing with the necessary infrastructure and processes developed and in place.
Report Numbers
E 1.99:doe und sc0005752
doe und sc0005752
Subject(s)
Other Subject(s)
Note
Published through SciTech Connect.
12/31/2012.
"doe und sc0005752"
Bradley, David Sherman.
Type of Report and Period Covered Note
Final; 04/18/2011 - 12/31/2012
Funding Information
SC0005752
View MARC record | catkey: 13801516